We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
Read MoreHide Full Article
Shares of Clovis Oncology, Inc. rallied 19.4% on Jun 15 after management reported initial data from the phase I/II LuMIERE study on FAP-2286, which demonstrates preliminary evidence of activity as a treatment and imaging agent across a wide range of solid tumors.
Data from the first two dose cohorts of the phase I portion of the LuMIERE study showed that nine patients treated with FAP-2286, labelled with lutetium-177 (177Lu-FAP-2286) demonstrated a manageable safety profile and encouraging evidence of activity. A confirmed partial response was also reported in one heavily pre-treated patient who completed six administrations of 177Lu-FAP-2286. In fact, no serious adverse event was observed in the study participants who were treated with 177Lu-FAP-2286.
Management plans to use the data from the phase I portion to determine the recommended dose and schedule in the phase II portion of the LuMIERE study. Clovis plans to start the phase II portion later this year.
The phase I/II LuMIERE study is evaluating the safety, pharmacokinetics, dosimetry and preliminary antitumor activity of FAP-2286 for treating solid tumors. CLVS is currently enrolling participants in the third dose cohort of this study.
Shares of Clovis have declined 64.3% in the year so far compared with the industry’s 30.2% fall.
Image Source: Zacks Investment Research
An investigator initiated phase I study is also evaluating the safety and tumor uptake of FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) as a novel imaging agent to identify metastatic cancer in patients with solid tumors. Clovis plans to use data from the study to begin phase II expansion cohorts for the treatment of multiple tumors by fourth-quarter 2022.
FAP-2286 is the lead candidate in Clovis’ targeted radionuclide therapy development program. Per management, the candidate is also the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP) to enter clinical development. FAP is a promising theranostic target with expression across many types of solid tumors.
Per management, this initial data supports Clovis’ hypothesis that FAP-2286 not only targets the tumor but also avoids off-target tissues. This data supports the potential clinical utility of the candidate to treat advanced solid tumors.
Clovis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics , Alkermes (ALKS - Free Report) and Sesen Bio . While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 60 days. Shares of ALKS have risen 18.8% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. Shares of ABEO have plunged 52% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have fallen 22.5% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Biodelivered an earnings surprise of 100%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
Shares of Clovis Oncology, Inc. rallied 19.4% on Jun 15 after management reported initial data from the phase I/II LuMIERE study on FAP-2286, which demonstrates preliminary evidence of activity as a treatment and imaging agent across a wide range of solid tumors.
Data from the first two dose cohorts of the phase I portion of the LuMIERE study showed that nine patients treated with FAP-2286, labelled with lutetium-177 (177Lu-FAP-2286) demonstrated a manageable safety profile and encouraging evidence of activity. A confirmed partial response was also reported in one heavily pre-treated patient who completed six administrations of 177Lu-FAP-2286. In fact, no serious adverse event was observed in the study participants who were treated with 177Lu-FAP-2286.
Management plans to use the data from the phase I portion to determine the recommended dose and schedule in the phase II portion of the LuMIERE study. Clovis plans to start the phase II portion later this year.
The phase I/II LuMIERE study is evaluating the safety, pharmacokinetics, dosimetry and preliminary antitumor activity of FAP-2286 for treating solid tumors. CLVS is currently enrolling participants in the third dose cohort of this study.
Shares of Clovis have declined 64.3% in the year so far compared with the industry’s 30.2% fall.
Image Source: Zacks Investment Research
An investigator initiated phase I study is also evaluating the safety and tumor uptake of FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) as a novel imaging agent to identify metastatic cancer in patients with solid tumors. Clovis plans to use data from the study to begin phase II expansion cohorts for the treatment of multiple tumors by fourth-quarter 2022.
FAP-2286 is the lead candidate in Clovis’ targeted radionuclide therapy development program. Per management, the candidate is also the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP) to enter clinical development. FAP is a promising theranostic target with expression across many types of solid tumors.
Per management, this initial data supports Clovis’ hypothesis that FAP-2286 not only targets the tumor but also avoids off-target tissues. This data supports the potential clinical utility of the candidate to treat advanced solid tumors.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. price | Clovis Oncology, Inc. Quote
Zacks Rank & Stocks to Consider
Clovis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics , Alkermes (ALKS - Free Report) and Sesen Bio . While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 60 days. Shares of ALKS have risen 18.8% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. Shares of ABEO have plunged 52% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have fallen 22.5% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Biodelivered an earnings surprise of 100%.